2015;66:1286 99. S4.4.4.1-15. Fleg JL, Forman DE, Berra K, et al. Secondary prevention of ath- erosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. Circulation. 2013;128:2422 46. S4.4.4.1-16. Garfinkel D, Ilhan B, Bahat G. Routine deprescribing of chronic medications to combat polypharmacy. Ther Adv Drug Saf. 2015;6:212 33. S4.4.4.1-17. Qi K, Reeve E, Hilmer SN, et al. Older peoples attitudes regarding polypharmacy, statin use and willingness to have statins depre- scribed in Australia. Int J Clin Pharm. 2015;37:949 57. S4.4.4.1-18. Rossello X, Pocock SJ, Julian DG. Long-term use of cardiovascu- lar drugs: challenges for research and for patient care. J Am Coll Cardiol. 2015;66:1273 85. S4.4.4.1-19. Han BH, Sutin D, Williamson JD, et al. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial. JAMA Intern Med. 2017;177:955 65. S4.4.4.1-20. Odden MC, Pletcher MJ, Coxson PG, et al. Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 yearsorolderintheUnitedStates.AnnInternMed.2015;162:533 41. 4.4.4.2. Young Adults (20 to 39 Years of Age) S4.4.4.2-1. Strong JP, Malcom GT, Oalmann MC, et al. The PDAY Study: natural history, risk factors, and pathobiology. Pathobiological Determinants of Atherosclerosis in Youth. Ann N Y Acad Sci. 1997;811:226 35.; discussion 35 7. S4.4.4.2-2. McGill HC Jr, McMahan CA, Herderick EE, et al. Effects of coro- nary heart disease risk factors on atherosclerosis of selected regions of the aorta and right coronary artery. PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol. 2000;20:836 45. S4.4.4.2-3. Williams RR, Hopkins PN, Hunt SC, et al. Population-based fre- quency of dyslipidemia syndromes in coronary-prone families in Utah. Arch Intern Med. 1990;150:582 8. S4.4.4.2-4. McGill HC Jr, McMahan CA, Malcom GT, et al. 